BioCentury | Oct 26, 2018
Company News
Stanford launches cannabinoid company Katexco for inflammatory disorders
...Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors...
...University, Stanford, Calif. Katexco Pharmaceuticals Corp., Toronto, Ontario Business: Autoimmune, Endocrine/Metabolic Mary Romeo Stanford University Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Katexco Pharmaceuticals Corp....
...University, Stanford, Calif. Katexco Pharmaceuticals Corp., Toronto, Ontario Business: Autoimmune, Endocrine/Metabolic Mary Romeo Stanford University Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Katexco Pharmaceuticals Corp....
